Page last updated: 2024-12-06
motropin
Description
Motropin is a synthetic growth hormone (GH) analog that is used to treat growth hormone deficiency in children and adults. It is a recombinant protein that is produced in bacteria. Motropin has a similar structure to natural human GH, but it has been modified to have a longer half-life and a more potent effect. The effects of motropin include increasing growth in children, improving body composition, and increasing bone density. Motropin is also being studied for its potential to treat a number of other conditions, including age-related muscle loss, heart failure, and cancer. It is studied because of its potential to improve growth and overall health in people with growth hormone deficiency and its potential to treat other conditions. The synthesis of motropin involves the expression of the gene for human GH in bacteria, followed by purification and formulation of the recombinant protein.'
motropin: narcotic analgesic antagonist in tropane series [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 64657 |
MeSH ID | M0103136 |
Synonyms (29)
Synonym |
HMS1474C13 |
74191-75-6 |
CBKINASE1_000100 |
EU-0067616 |
AH-262/02649058 |
8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-morpholin-4-ylpropanoate |
CBDIVE_010312 |
CBKINASE1_012500 |
OPREA1_830271 |
OPREA1_224990 |
CHEMDIV3_000409 |
NCGC00175156-01 |
8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-(morpholin-4-yl)propanoate |
STK383757 |
(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-morpholin-4-ylpropanoate |
AKOS000573616 |
CCG-15387 |
motropine |
80619-62-1 |
motropin |
AB00076520-01 |
AKOS021984015 |
8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-(4-morpholinyl)propanoate # |
propionic acid, 3-morpholino-, 8-aza-8-methylbicyclo[3,2,1]oct-3-yl ester |
JBICFMQWCKPGRR-UHFFFAOYSA-N |
8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-(4-morpholinyl)propanoate |
8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-(morpholin-4-yl)propanoate |
DTXSID60995660 |
BRD-A79304833-001-02-8 |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |